Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Time-release stimulant effective for once-daily treatment of ADHD

05.08.2002


First amphetamine-based long-acting stimulant offers all-day symptom control in children


A research team led by a Massachusetts General Hospital investigator has found that a long-acting form of the stimulant medication Adderall is effective in controlling symptoms of attention-deficit/hyperactivity disorder (ADHD) in children when taken in a single morning dose. The standard form of Adderall, which is made up of several amphetamine-based drugs, is only effective for four hours. This new formulation joins other long-acting stimulants, such as extended-release methylphenidate (Ritalin), in giving patients with ADHD a greater choice of medication. The report appears in the August issue of Pediatrics.

"Long-acting stimulants are very beneficial for children with ADHD, who otherwise have to go to the nurse’s office during the school day to receive their medication. And timed-release dosage avoids having frequent peaks and valleys of medication levels, giving the patient a more stable therapeutic environment," says Joseph Biederman, MD, director of Pediatric Psychopharmacology at MGH and the study’s lead author. "This medication gives us another treatment opportunity for those who cannot tolerate other stimulant drugs."

More than 500 children aged 6 to 12 who met standard diagnostic criteria for ADHD enrolled in the study at 47 sites across the country. Participants were randomly divided into four groups, and after a one-week "washout" period in which all participants received a placebo medication, three of the four groups began taking a 10 mg daily dose of the timed-release medication. The fourth group continued on placebo. After a week of 10 mg dosage, two of the three medication groups switched to a 20 mg dosage. And after another week, one group advanced to a 30 mg daily dosage. The study was double-blinded, meaning that study participants, their parents and the treating physicians did not know what dosages participants were receiving.



Throughout the four-week study period, participants received weekly evaluations from their physicians, and both parents and teachers completed weekly evaluations of the children’s behavior at home and at school. In addition, the children received complete physical examinations, including standard laboratory tests, before and at the end of the study.

Based on the results of both the teachers’ and parents’ evalutions, which used standardized behavioral surveys, even the 10 mg dosages of the timed-release medication produced significant behavioral improvements versus placebo throughout the day and into the evening. The higher dosages produced greater improvement, with the 30 mg dosage producing the best evaluations from both teachers and parents. No major adverse side-effects were reported.

The researchers note that not only does the long-acting medication eliminate the need for in-school administration - which should reduce missed doses and avoid publicly identifying students as having ADHD - but also a steady medication effect throughout the day will avoid the emergence of symptoms when drug levels begin to drop. In addition, symptom control persists into the evening, allowing coverage of homework and other after-school activities.

"By making ADHD treatment easier, less cumbersome and more private, long-acting stimulants can help improve patient compliance, resulting in better symptom control and an improved overall outcome for patients," says Biederman, who is also a professor of psychiatry at Harvard Medical School.


Biederman’s co-authors are Frank Lopez, MD, Children?s Development Center, Maitland, Fla.; Samuel Boellner, MD, Clinical Study Centers, Little Rock, Ark.; and Mark Chandler, MD, North Carolina Neuropsychiatry, Chapel Hill, N.C. The study was supported by a grant from Shire Pharmaceuticals, the manufacturer of Adderall.

The Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $300 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, transplantation biology and photomedicine. In 1994, the MGH joined with Brigham and Women’s Hospital to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups and nonacute and home health services.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>